Tavaborole

Oxaborole Antifungal — DERMATOLOGICALS

Key facts

Tavaborole is an ofp drug in the Oxaborole Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Protein Synthesis Inhibitors. DrugCentral lists 6 molecular targets, including Carbonic anhydrase, CAN2 and CA2. Recorded indications include Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes, Onychomycosis due to Trichophyton rubrum and Onychomycosis of toenails.

• Approval status: ofp (first approved 2014 by the FDA).
• Drug class: Oxaborole Antifungal.
• Mechanism of action: Protein Synthesis Inhibitors.
• Molecular targets: Carbonic anhydrase, CAN2, CA2 and CDC60 (6 listed in DrugCentral).
• Indications: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes, Onychomycosis due to Trichophyton rubrum and Onychomycosis of toenails.
• ATC code: D01AE24 (Other antifungals for topical use).
• Molecular formula: C7H6BFO2; molecular weight 151.93 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Onychomycosis due to dermatophyte
• Onychomycosis due to Trichophyton mentagrophytes
• Onychomycosis due to Trichophyton rubrum
• Onychomycosis of toenails

Mechanism & targets

• Mechanism of action (MoA): Protein Synthesis Inhibitors
• Established pharmacologic class: Oxaborole Antifungal

Molecular targets (6)

Target	Gene	Action	Activity
Carbonic anhydrase	—	unknown	Ki 7.14
Carbonic anhydrase 2	CAN2	unknown	Ki 7.05
Carbonic anhydrase 2	CA2	unknown	Ki 6.33
Leucine--tRNA ligase, cytoplasmic	CDC60	unknown	Ki 5.73
Carbonic anhydrase 1	CA1	unknown	Ki 5.70
Leucine-tRNA ligase	—	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2014-07-07	FDA	—	ANACOR PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
D01AE24	DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Other antifungals for topical use

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Tavaborole is on its molecule page.

• Molecular formula: C₇H₆BFO₂
• Molecular weight: 151.93 g/mol
• CAS number: —
• InChIKey: LFQDNHWZDQTITF-UHFFFAOYSA-N
• PubChem CID: 11499245

OB1OCC2=C1C=CC(F)=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tavaborole used for?

DrugCentral lists the following indications for Tavaborole: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes, Onychomycosis due to Trichophyton rubrum and Onychomycosis of toenails.

How does Tavaborole work?

Tavaborole is classified as Protein Synthesis Inhibitors; its molecular targets in DrugCentral include Carbonic anhydrase, CAN2, CA2 and CDC60.

When was Tavaborole first approved?

Tavaborole was first approved by the FDA in 2014.

What drug class does Tavaborole belong to?

Tavaborole is in the Oxaborole Antifungal class.

What is the chemical formula of Tavaborole?

Tavaborole has the molecular formula C7H6BFO2 and a molecular weight of 151.93 g/mol.

Sources

• DrugCentral drug card 4877 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL443052 — compound record and bioactivity
• PubChem CID 11499245 — chemical identifiers
• DrugBank DB09041 — drug record
• FDA UNII K124A4EUQ3 — substance identity
• DailyMed: FDA labels for Tavaborole — current prescribing information (label search)
• UniProt P00918 (CA2) — target protein
• UniProt P00915 (CA1) — target protein

How this page is built: methodology · editorial policy & corrections.